A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer

NCT07455071 · clinicaltrials.gov ↗
NA
Phase
NOT_YET_RECRUITING
Status
9
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Peking University Third Hospital